On September 30 2023, NEKTAR THERAPEUTICS ($NASDAQ:NKTR) reported total revenue of USD 24.1 million for the third quarter of fiscal year 2023, a 2.2% increase from the same period in 2022. Net income was -45.8 million, a slight decrease from -59.0 million reported in the same quarter a year prior.
On Tuesday, NEKTAR THERAPEUTICS reported its third quarter fiscal year 2023 earnings results, with the stock opening at $0.5 and closing at $0.5, up by 3.4% from its prior closing price of $0.5. The company delivered strong financial performance, beating analyst estimates for both revenue and earnings. NEKTAR THERAPEUTICS attributed the strong performance to its continued focus on innovation and commitment to developing high-value therapeutics. The company’s pipeline of products continues to expand, with the potential to bring transformative treatments to patients suffering from cancer, pain, and other chronic diseases. The company is also rapidly expanding its research and development capabilities in order to capitalize on emerging opportunities in biotechnology.
In addition, NEKTAR THERAPEUTICS is continuing to invest in manufacturing processes to ensure consistent and reliable delivery of products to patients and healthcare providers. Overall, NEKTAR THERAPEUTICS is well-positioned to capitalize on the growing demand for innovative therapies across the globe. Investors can look forward to the company’s upcoming earnings report in fiscal year 2023 as it continues to deliver strong results. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Nektar Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Nektar Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Nektar Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Nektar Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Nektar Therapeutics Stock Fair Value
At GoodWhale, we have analyzed the fundamentals of NEKTAR THERAPEUTICS and come to the following conclusion. Our proprietary Valuation Line has calculated that NEKTAR THERAPEUTICS’s intrinsic value is around $1.9 per share. At the moment, NEKTAR THERAPEUTICS stock is trading at around $0.5 – a staggering 74.1% below its intrinsic value. This presents a great opportunity for investors to buy the stock at a discount and potentially benefit from future price appreciation. More…
Star Chart Analysis
The company’s competitors include Bristol-Myers Squibb Co, Merck & Co Inc, Eli Lilly and Co.
– Bristol-Myers Squibb Co ($NYSE:BMY)
Bristol-Myers Squibb Co, a pharmaceutical company, has a market cap of 155.38B as of 2022. The company has a Return on Equity of 17.43%. Bristol-Myers Squibb Co is engaged in the discovery, development, manufacture, and sale of biopharmaceutical products.
– Merck & Co Inc ($NYSE:MRK)
Merck & Co Inc is a global health care company that offers a wide range of products and services to help people lead healthier lives. The company has a market cap of 247.53B as of 2022 and a return on equity of 28.84%. The company’s products and services include prescription and over-the-counter medications, vaccines, biologic therapies, and consumer care and animal health products. The company also provides services such as marketing, research, and development, and manufacturing. Merck & Co Inc’s mission is to help people around the world live healthier lives by providing them with the products and services they need.
– Eli Lilly and Co ($NYSE:LLY)
Eli Lilly and Co is a pharmaceutical company with a market cap of 333.81B as of 2022. Its return on equity is 45.88%. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly and Co manufactures and markets pharmaceutical products in the United States, Europe, and Canada. The company’s products include Zyprexa, Prozac, Cymbalta, and Cialis.
Investors have responded positively to Nektar Therapeutics‘ Q3 fiscal year 2023 earnings results, with the stock price increasing on the day of release. Total revenue for the quarter rose 2.2% year-over-year, though the company reported a net loss of -45.8 million. While revenue growth was encouraging, investors will be closely watching the company’s ability to improve profitability in future quarters. With its strong pipeline of drugs in development, Nektar Therapeutics has the potential to become an attractive long-term investment option.